Two patients with cancer showed partial tumor shrinkage after infusions of a novel immune-boosting treatment derived from red blood cells, its maker Rubius Therapeutics said Monday.
Rubius said the preliminary results of its early-stage clinical trial provided “clinical validation” of its treatment, called RTX-240. However, the company was unable to show data proving RTX-240 triggered the expected immune system attack against the patients’ tumors, leaving questions about its future unanswered.
Any doubts raised by the mixed study results were swept aside by investors in Monday trading, with Rubius shares rising 70% to $28 — an all-time high stock price. The company now carries a market value of $2.5 billion.
About the Author Reprints
